Apellis Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Apellis Pharmaceuticals, Inc. (APLS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are APLS insiders buying or selling?
In the last 12 months, Apellis Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 28 sales ($3.1M) — net selling of $3.1M. Since May 2018, Trabud has recorded 366 Form 4 filings for APLS: 8 buys ($42.2M) and 358 sells ($157.5M).
Source: SEC EDGAR Form 4
What stands out
- No Apellis Pharmaceuticals, Inc. insider made an open-market purchase in the last 12 months; the 28 reported open-market sales totaled $3.1M.
Key Statistics (May 2018 – Feb 13, 2026)
Total Form 4 filings
366
SEC EDGAR
Insider filers
19
Insider buys (8)
$42.2M
Insider sells (358)
$157.5M
Insider sentiment
Net sellingNet insider flow of $115.3M in net selling since May 2018, and $3.1M in net selling over the last 12 months.
Recent APLS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | Mark Jeffrey Delong | Chief Business & Strat Officer | Sale | 368 | $22.15 | $8.2K | SEC ↗ |
| Jan 23, 2026 | Caroline Baumal | Chief Medical Officer | Sale | 2.8K | $21.77 | $60.9K | SEC ↗ |
| Jan 23, 2026 | James George Chopas | VP/Chief Accounting Officer | Sale | 2.1K | $21.77 | $44.9K | SEC ↗ |
| Jan 23, 2026 | Mark Jeffrey Delong | Chief Business & Strat Officer | Sale | 3.4K | $21.77 | $73.4K | SEC ↗ |
| Jan 23, 2026 | Pascal Deschatelets | Chief Scientific Officer | Sale | 5.9K | $21.77 | $129.0K | SEC ↗ |
| Jan 23, 2026 | Cedric Francois | Chief Executive Officer | Sale | 27.2K | $21.77 | $591.8K | SEC ↗ |
| Jan 23, 2026 | Nur Nicholson | Chief Technical Officer | Sale | 7.7K | $21.77 | $168.1K | SEC ↗ |
| Jan 23, 2026 | Timothy Eugene Sullivan | Chief Financial Officer | Sale | 10.3K | $21.77 | $223.9K | SEC ↗ |
| Jan 23, 2026 | David O. Watson | General Counsel | Sale | 7.8K | $21.77 | $170.5K | SEC ↗ |
| Jan 21, 2026 | Caroline Baumal | Chief Medical Officer | Sale | 1.9K | $19.79 | $37.3K | SEC ↗ |
| Jan 21, 2026 | James George Chopas | VP/Chief Accounting Officer | Sale | 726 | $19.79 | $14.4K | SEC ↗ |
| Jan 21, 2026 | Mark Jeffrey Delong | Chief Business & Strat Officer | Sale | 1.3K | $19.79 | $26.4K | SEC ↗ |
| Jan 21, 2026 | Pascal Deschatelets | Chief Scientific Officer | Sale | 909 | $19.79 | $18.0K | SEC ↗ |
| Jan 21, 2026 | Cedric Francois | Chief Executive Officer | Sale | 8.2K | $19.79 | $161.9K | SEC ↗ |
| Jan 21, 2026 | Nur Nicholson | Chief Technical Officer | Sale | 2.2K | $19.79 | $43.6K | SEC ↗ |
| Jan 21, 2026 | Timothy Eugene Sullivan | Chief Financial Officer | Sale | 2.9K | $19.79 | $57.2K | SEC ↗ |
| Jan 21, 2026 | David O. Watson | General Counsel | Sale | 2.5K | $19.79 | $49.0K | SEC ↗ |
| Jan 15, 2026 | James George Chopas | VP/Chief Accounting Officer | Sale | 873 | $22.19 | $19.4K | SEC ↗ |
| Jan 15, 2026 | Mark Jeffrey Delong | Chief Business & Strat Officer | Sale | 1.8K | $22.19 | $39.5K | SEC ↗ |
| Jan 15, 2026 | Pascal Deschatelets | Chief Scientific Officer | Sale | 2.3K | $22.19 | $50.5K | SEC ↗ |
| Jan 15, 2026 | Cedric Francois | Chief Executive Officer | Sale | 10.2K | $22.19 | $226.0K | SEC ↗ |
| Jan 15, 2026 | Nur Nicholson | Chief Technical Officer | Sale | 2.6K | $22.19 | $58.1K | SEC ↗ |
| Jan 15, 2026 | Timothy Eugene Sullivan | Chief Financial Officer | Sale | 3.9K | $22.19 | $85.6K | SEC ↗ |
| Jan 15, 2026 | David O. Watson | General Counsel | Sale | 5.8K | $22.19 | $128.2K | SEC ↗ |
| Jan 6, 2026 | Caroline Baumal | Chief Medical Officer | Sale | 3.0K | $25.53 | $77.1K | SEC ↗ |
Showing the 25 most recent of 366 Form 4 filings for Apellis Pharmaceuticals, Inc..
Most active APLS insiders
- Alec Machiels42 filings
- Federico Grossi42 filings
- Cedric Francois38 filings
- Pascal Deschatelets38 filings
- David O. Watson31 filings
Ask anything about APLS insider activity
Use Trabud's AI agent to query Apellis Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me APLS CEO purchases this year" or compare it against any other ticker.
Open the AI agentAPLS insider trading FAQ
Are Apellis Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, Apellis Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 28 sales ($3.1M) — net selling of $3.1M. Since May 2018, Trabud has recorded 366 Form 4 filings for APLS: 8 buys ($42.2M) and 358 sells ($157.5M). Over the full record that is net selling of $115.3M.
How many insiders trade APLS stock?
19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Apellis Pharmaceuticals, Inc.. The most recent filing was accepted on Feb 13, 2026.
Where does Trabud get APLS insider trading data?
All APLS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.